Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nomegestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.69 |
| ▸ | AR | P10275 | 4/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | SHBG | P04278 | 1/20 | 0.49 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nomegestrol SCHEMBL139763 | 0.98 | LMNA (0.80) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL19760878 | 0.98 | LMNA (0.80) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL27486762 | 0.97 | LMNA (0.76) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL6415665 | 0.97 | LMNA (0.79) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL4913845 | 0.91 | LMNA (0.74) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Acetic Acid SCHEMBL282894 | 0.89 | CYP2C19 (0.62) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| SCHEMBL9322389 | 0.87 | LMNA (0.82) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| SCHEMBL141181 | 0.87 | CYP2C19 (0.64) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol Acetate SCHEMBL8817628 | 0.82 | PGR (1.00) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol Acetate SCHEMBL37517 | 0.82 | PGR (1.00) | LMNACYP3A4CYP2C9CYP2C19PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2244 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616703-B2 | Methods of contraception using nomegestrol acetate and estradiol | Theramex HQ UK Limited (GB) | 2026-05-05 | — | — | US | claimed |
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| US-20250360081-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | TRIASTEK INC (CN) | 2025-11-27 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| EP-4604932-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2025-08-27 | — | — | EP | claimed |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2025-08-21 | — | — | US | claimed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| WO-2024175760-A1 | METHODS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-08-29 | — | — | WO | claimed |
| EP-4420720-A2 | USE OF COMBINED ORAL CONTRACEPTIVES CONTAINING NOMEGESTROL ACETATE AND ESTRADIOL | Theramex HQ UK Limited (GB) | 2024-08-28 | — | — | EP | claimed |
| EP-0783310-B1 | NOVEL HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES | THERAMEX (MC) | 2002-10-09 | — | — | EP | claimed |
| US-20020107230-A1 | Methods and formulations for the treatment of female sexual dysfunction | BARR LABORATORIES, INC. | 2002-08-08 | — | — | US | claimed |
| WO-2002051420-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ENDEAVOR PHARMACEUTICALS (US) | 2002-07-04 | — | — | WO | claimed |
| CN-1083259-C | Transdermal matrix system | LHD LAB HYGIENE DIETETIQUE (FR) | 2002-04-24 | — | — | CN | claimed |
| CN-1301146-A | Topical hormonal composition with systemic effect | THERAMEX (MC) | 2001-06-27 | — | — | CN | claimed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | claimed |
| CN-1239893-A | Hormonal composition consisting of an estrogenic compound and a progestational compound | THERAMEX (MC) | 1999-12-29 | — | — | CN | claimed |
| US-5955454-A | METHYLATED CYCLODEXTRIN; NONTOXIC, SIDE EFFECT REDUCTION, BIOAVAILABILITY | ADIR ET COMPAGNIE (FR) | 1999-09-21 | — | — | US | claimed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | claimed |
| US-5891867-A | ORAL ADMINISTRATION OF AN ESTROGEN ALONE FOLLOWED BY AN ESTROGEN PROGESTOGEN COMBINATION AND THEN A PLACEBO. | LABORATOIRE THERAMEX (MC) | 1999-04-06 | — | — | US | claimed |